The research team applied PhIP-Seq using the VirScan phage-display library to profile antibody binding across the full Epstein-Barr virus proteome at peptide-level resolution. The cohort included 115 adults from sub-Saharan Africa; the authors reported 43 participants with HIV-1 and 72 without. The assay generated high-resolution maps of which EBV peptides were targeted by circulating antibodies in each individual. The source did not report interventional procedures, therapeutic dosing, or longitudinal sampling in this dataset; this work is presented as a cross-sectional antibody profiling study.
Data indicated that several EBV proteins were consistently immunodominant among study participants. EBNA1, EBNA2, EBNA3B, and the viral capsid protein BFRF3 were the proteins most frequently targeted by antibodies. The cohort showed common recognition of these proteins regardless of HIV-1 status, although absolute magnitudes and the percentage of seropositive individuals varied across the proteome. The authors reported that many epitopes were shared across participants, pointing to recurrent humoral targets in natural EBV infection.
Comparative peptide-level analyses between EBV Type 1 and Type 2 sequences uncovered differential antibody reactivity centered on EBNA2. The study team observed increased antibody recognition near the C-terminal transactivation domain (C-TAD) of EBNA2 for Type 1 strains. This pattern was described as strain-specific — antibody reactivity differed depending on whether the peptide derived from Type 1 or Type 2 EBNA2 — suggesting that sequence variation in the C-TAD alters antigenicity and shapes humoral recognition at that locus.
Within the EBNA1 protein, investigators identified a single region containing the nuclear localization sequence (NLS) as the most frequently targeted epitope across the EBV proteome. Many individuals showed antibody binding to peptides spanning this NLS-containing segment. The finding implies concentrated humoral attention to a functionally relevant site of EBNA1, which may reflect antigen exposure or structural features that favor B cell recognition.
The study reported broader and, in many cases, stronger anti-EBV antibody responses in people with HIV-1 (PWH) compared with HIV-uninfected participants. Specifically, a higher percentage of PWH had antibodies reactive to the majority of EBV proteins included in the VirScan library. The authors suggest this expanded repertoire likely reflects increased EBV antigen exposure in PWH, plausibly driven by viral reactivation events and HIV-associated alterations in immune control. The source did not provide longitudinal virologic measures of EBV reactivation or quantitative viral loads tied to individual antibody profiles; such links were inferred from cross-sectional differences.
Because EBV is causally linked to several malignancies, the altered humoral repertoire in PWH may have clinical relevance. The authors noted that higher exposure to EBV antigens in PWH could relate to their increased risk for EBV-associated cancers, such as lymphomas. They proposed that antibody profiling at high resolution might yield candidate prognostic biomarkers for cancer risk among PWH. The paper explicitly called for longitudinal studies to determine whether the observed humoral differences can predict oncologic outcomes, since this cross-sectional dataset cannot establish temporal or causal relationships.
This work offers a comprehensive serological snapshot but has limits intrinsic to cross-sectional proteome-wide profiling. The source did not report longitudinal follow-up, prognostic performance statistics, or direct measures of EBV reactivation tied to each participant’s antibody pattern. The authors recommend longitudinal validation to test whether the expanded anti-EBV repertoire in PWH precedes or predicts EBV-associated malignancy. Additional unanswered questions documented by the source include whether specific peptide reactivities correlate with clinical endpoints and whether these signals persist after antiretroviral-mediated immune reconstitution. These are the next steps the study team identified for future research.